ADPT in the 13F filings
Adaptive Biotechnologies Corp · CUSIP 00650F109
- Quarter end
- 30 Jun 2026
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 3 Aug 2026
- Managers listing it
- 29
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q1 2026 and Q2 2026; 4 listed it in both
- Shares listed
- 58,767,618
- combined, among listed positions
- Reported value
- $1.3bn
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 12 buyers (opened or added shares) and 20 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +4,268,258.
Managers listing ADPT in Q2 2026
29 of 29 holders
Largest increases and reductions, by shares
Increases
- D. E. Shaw & Co.existing position · 4,625,859 shares now+2,660,249
- Wellington Management Group LLPexisting position · 5,911,366 shares now+2,053,944
- T. Rowe Price Associates Incexisting position · 2,665,308 shares now+1,099,095
- Jane Street Group LLCexisting position · 1,590,513 shares now+908,331
- Freestone Grove Partners LPnew position · 881,688 shares now+881,688
Reductions
- Invesco Ltdexisting position · 3,094,011 shares now-1,356,055
- Millennium Management LLCexisting position · 504,909 shares now-576,457
- Tudor Investment Corpexisting position · 543,485 shares now-242,796
- Schonfeld Strategic Advisors LLCexisting position · 51,183 shares now-211,016
- Citadel Advisors LLCexisting position · 181,356 shares now-181,977
New positions and exits
New (1)
Exited (5)
- Point72 Asset Management LPwas $14m
- Brevan Howard Capital Management LPwas $2.4m
- Two Sigma Investments LPwas $1.6m
- Caxton Associates LLPwas $500k
- Farallon Capital Management LLCwas $153k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2019 | 8 | $1.9bn | n.a. | n.a. |
| Q3 2019 | 2 | $1.2bn | n.a. | n.a. |
| Q4 2019 | 5 | $1.2bn | n.a. | n.a. |
| Q1 2020 | 4 | $1.1bn | n.a. | n.a. |
| Q2 2020 | 8 | $1.9bn | n.a. | n.a. |
| Q3 2020 | 11 | $2.2bn | n.a. | n.a. |
| Q4 2020 | 10 | $2.7bn | n.a. | n.a. |
| Q1 2021 | 6 | $1.9bn | n.a. | n.a. |
| Q2 2021 | 7 | $2.0bn | n.a. | n.a. |
| Q3 2021 | 7 | $1.7bn | n.a. | n.a. |
| Q4 2021 | 7 | $1.5bn | n.a. | n.a. |
| Q1 2022 | 5 | $525m | n.a. | n.a. |
| Q2 2022 | 3 | $311m | n.a. | n.a. |
| Q3 2022 | 3 | $281m | n.a. | n.a. |
| Q4 2022 | 3 | $300m | n.a. | n.a. |
| Q1 2023 | 3 | $347m | n.a. | n.a. |
| Q2 2023 | 3 | $272m | n.a. | n.a. |
| Q3 2023 | 4 | $262m | n.a. | n.a. |
| Q4 2023 | 5 | $232m | 2 | 2 |
| Q1 2024 | 3 | $131m | 1 | 1 |
| Q2 2024 | 3 | $151m | 1 | 0 |
| Q3 2024 | 3 | $214m | 2 | 0 |
| Q4 2024 | 4 | $239m | 2 | 1 |
| Q1 2025 | 3 | $283m | 1 | 1 |
| Q2 2025 | 5 | $404m | 2 | 2 |
| Q3 2025 | 5 | $503m | 2 | 2 |
| Q4 2025 | 6 | $535m | 21 | 13 |
| Q1 2026 | 6 | $457m | 19 | 14 |
| Q2 2026 | 7 | $946m | 12 | 20 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
ADPT and GILD →ADPT and AMGN →ADPT and ARGX →Choose a stock to compare with ADPT →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own ADPT, latest filings →Back to the 13F Explorer →